Education
About Us
Working with TipRanks
Follow Us
LIDDS AB (DE:5LD)
BERLIN:5LD
5LD Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€441.87K
Enterprise Value€6.79M
Total Cash (Recent Filing)€1.73M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding136,463,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.24
Price to Sales (P/S)432.85
P/FCF Ratio-2.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
5LD FAQ
What was LIDDS AB’s price range in the past 12 months?
LIDDS AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is LIDDS AB’s market cap?
LIDDS AB’s market cap is €441.87K.
When is LIDDS AB’s upcoming earnings report date?
LIDDS AB’s upcoming earnings report date is Feb 19, 2026 which is in 55 days.
How were LIDDS AB’s earnings last quarter?
LIDDS AB released its earnings results on Nov 20, 2025. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is LIDDS AB overvalued?
According to Wall Street analysts LIDDS AB’s price is currently Overvalued.
Does LIDDS AB pay dividends?
LIDDS AB does not currently pay dividends.
What is LIDDS AB’s EPS estimate?
LIDDS AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LIDDS AB have?
LIDDS AB has 136,463,330 shares outstanding.
What happened to LIDDS AB’s price movement after its last earnings report?
LIDDS AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of LIDDS AB?
Currently, no hedge funds are holding shares in DE:5LD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LIDDS AB
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Technical Analysis
Diagonal Bio AB
―
Stayble Therapeutics AB
―
CombiGene AB
―
Fluicell AB
―
QuiaPEG Pharmaceuticals Holding AB
―